DD vs TRDA · P/E 127, rev $12.39B vs P/E 12, rev $210.8M
Dupont De Nemours Inc (DD) versus Entrada Therapeutics Inc (TRDA) — a side-by-side from cached financials, not a winner call.
Dupont De Nemours Inc (DD) is a specialty chemicals company listed on US.
Entrada Therapeutics Inc (TRDA) is a biotechnology company listed on US.
Latest reported DD revenue for 2024-12-31 was $12.39B. Net income was $738.0M. Revenue was up 2.6% from 2023-12-31 to 2024-12-31. DD currently screens at market cap $19.61B and trailing P/E 127.4.
Latest reported TRDA revenue for 2024-12-31 was $210.8M. Net income was $65.6M. Revenue was up 63.4% from 2023-12-31 to 2024-12-31. TRDA currently screens at market cap $274.4M and trailing P/E 12.5.
DD currently screens at market cap $19.61B and trailing P/E 127.4. TRDA currently screens at market cap $274.4M and trailing P/E 12.5.
Not investment advice. Open the DD and TRDA stock pages for the full models.
Not investment advice.